Literature DB >> 16239760

Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments.

Kelvin L Chou1, Susan Messing, David Oakes, Peter D Feldman, Alan Breier, Joseph H Friedman.   

Abstract

OBJECTIVES: To describe further the phenomenology of drug-induced psychosis (DIP) in patients with Parkinson disease (PD) and assess which items on two common psychosis rating instruments-the Brief Psychiatric Rating Scale (BPRS) and the Neuropsychiatric Inventory (NPI)-are the best measure of DIP by comparing them with the Clinical Global Impression Scale (CGIS).
METHODS: Baseline data from two placebo-controlled, double-blind studies of olanzapine in PD patients with DIP were collected and analyzed.
RESULTS: A total of 157 of 160 patients had hallucinations, with visual hallucinations being the most common (97% of subjects), followed by auditory (48%), tactile (23%), and olfactory (16%). Seventy-six percent of subjects experienced delusions, and all types of delusions occurred with relatively equal frequency. The CGIS correlated with suspiciousness, hallucinatory behavior, unusual thought content, and hostility on the BPRS; and delusions, hallucinations, agitation, aberrant motor behavior, and sleep on the NPI.
CONCLUSION: Nonvisual hallucinations and delusions may occur more frequently in DIP than previously thought. These symptoms, plus agitation and hostility, may ultimately be the best measure of DIP in patients with PD.

Entities:  

Mesh:

Year:  2005        PMID: 16239760     DOI: 10.1097/01.wnf.0000180228.77802.32

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  13 in total

1.  The changing face of Parkinson's disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria.

Authors:  Gilles Fénelon; Thierry Soulas; Franck Zenasni; Laurent Cleret de Langavant
Journal:  Mov Disord       Date:  2010-04-30       Impact factor: 10.338

2.  Neuropsychiatric Complications of Parkinson Disease Treatments: Importance of Multidisciplinary Care.

Authors:  Jacob Taylor; William S Anderson; Jason Brandt; Zoltan Mari; Gregory M Pontone
Journal:  Am J Geriatr Psychiatry       Date:  2016-09-03       Impact factor: 4.105

Review 3.  Evidence for the use of pimavanserin in the treatment of Parkinson's disease psychosis.

Authors:  Harini Sarva; Claire Henchcliffe
Journal:  Ther Adv Neurol Disord       Date:  2016-10-03       Impact factor: 6.570

Review 4.  Hallucinations in Parkinson disease.

Authors:  Nico J Diederich; Gilles Fénelon; Glenn Stebbins; Christopher G Goetz
Journal:  Nat Rev Neurol       Date:  2009-06       Impact factor: 42.937

5.  [Evidence-based treatment of psychosis associated with Parkinson's disease].

Authors:  R Haussmann; M Bauer; M Donix
Journal:  Nervenarzt       Date:  2016-05       Impact factor: 1.214

Review 6.  The psychosis spectrum in Parkinson disease.

Authors:  Dominic H Ffytche; Byron Creese; Marios Politis; K Ray Chaudhuri; Daniel Weintraub; Clive Ballard; Dag Aarsland
Journal:  Nat Rev Neurol       Date:  2017-01-20       Impact factor: 42.937

Review 7.  Pharmacology of hallucinations: several mechanisms for one single symptom?

Authors:  Benjamin Rolland; Renaud Jardri; Ali Amad; Pierre Thomas; Olivier Cottencin; Régis Bordet
Journal:  Biomed Res Int       Date:  2014-06-04       Impact factor: 3.411

8.  A novel scale to assess psychosis in patients with parkinson's disease.

Authors:  William G Ondo; Sana Sarfaraz; MinJae Lee
Journal:  J Clin Mov Disord       Date:  2015-12-01

9.  A questionnaire-based (UM-PDHQ) study of hallucinations in Parkinson's disease.

Authors:  Spiridon Papapetropoulos; Heather Katzen; Anette Schrag; Carlos Singer; Blake K Scanlon; Daniel Nation; Alexandra Guevara; Bonnie Levin
Journal:  BMC Neurol       Date:  2008-06-20       Impact factor: 2.474

10.  A fixed-dose randomized controlled trial of olanzapine for psychosis in Parkinson disease.

Authors:  Michelle J Nichols; Johanna M Hartlein; Meredith Ga Eicken; Brad A Racette; Kevin J Black
Journal:  F1000Res       Date:  2013-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.